Acetazolamide for Treatment Resistant Schizophrenia (APTS)

A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Study Overview

• Status: Recruiting
• Conditions: Schizophrenia; Schizo Affective Disorder
• Intervention / Treatment: Drug: Acetazolamide; Drug: Placebo

Detailed Description

Schizophrenia (SZ) afflicts over 21 million people worldwide. Persons with SZ have a 10% suicide rate and their lifespan is curtailed by over 25 years. There is an urgent need for efficacious antipsychotic drugs (APDs), particularly, second line drugs, because only 30-40% of APD-treated patients attain remission and 30% of patients show little or no response. Currently, Clozapine is the only reliable second line APD, but it can cause serious blood dyscrasias. To fill the void, the investigators have conducted systematic reviews of prior data and in silico searches. In a prior double-blind crossover randomized placebo-controlled trial (RCT), adjunctive Acetazolamide (ACZ) caused ~20% improvement in positive and negative symptom scores when added to APDs among partially-responsive patients with SZ (ACZ 2G/day). No patients dropped out. The RCT is supported by several other open trials. ACZ also reduces weight, thus it could combat weight gain, a common APD side effect. Independently, our systematic in silico strategy based on protein networks and gene expression profiles also identified Acetazolamide (ACZ) as a repurposable drug for SZ.

ACZ crosses the blood-brain barrier. It is used to treat CNS diseases such as refractory seizures and idiopathic intracranial hypertension. Used for over 50 years, its side effects (SE) and adverse effects (AE) are well known and are manageable. It is a potent, specific inhibitor of carbonic anhydrase (CA), which catalyzes the conversion of CO2 to HCO3- and H+. CA is localized to pre-synaptic terminals and glial cells. It modulates GABAergic excitation, long-term synaptic transformation, attentional gating of memory storage and cerebrospinal fluid formation. Post-mortem brain and serological studies show raised CA levels in patients with psychotic/mood disorders. Several APDs also inhibit CA. The investigators thus postulate brain CA inhibition as the therapeutic target for ACZ in SZ.

The investigators propose a double-blind, crossover RCT for SZ using adjunctive ACZ. To maximize the risk/benefit ratio, the investigators will enroll inpatients and outpatients with treatment resistant SZ (trSZ) who meet defined criteria (N=60 RCT completers). ACZ or placebo will be added to prescribed APDs for 8 weeks utilizing the Sequential Parallel Comparison Design to maximize power. The investigators have extensive experience with RCTs. The investigators will ensure timely recruitment by approaching a large group of patients we serve, across 2 sites. If ACZ is beneficial, in future studies the investigators will pursue its implementation for trSZ, and seek variables associated with treatment response.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Vishwajit L Nimgaonkar, M.D., Ph.D.; Phone Number: 412-246-6356; Email: vishwajitNL@upmc.edu
• Study Contact Backup: Name: Maribeth A Wesesky, BPS; Phone Number: 4122957017; Email: weseskyma@upmc.edu

Study Locations

• India
  • Bangalore, India
    • Recruiting
    • St John's Medical College Hospital
    • Contact: Smita N Deshpande, M.D.; Phone Number: (91)- 93126-54702; Email: smitadeshp@gmail.com
    • Contact: Triptish Bhatia, Ph.D.; Phone Number: (91)-11-23404363; Email: bhatiatriptish@yahoo.co.in
    • Sub-Investigator: Ashok Mysore, M.D.
    • Sub-Investigator: Anil Kakunje, M.D.
    • Principal Investigator: Smita Deshpande, M.D.
• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Recruiting
      • University of Pittsburgh
      • Contact: Maribeth A Wesesky, BPS; Phone Number: 412-295-7017; Email: weseskyma@upmc.edu
      • Sub-Investigator: Satish Iyengar, Ph.D.
      • Sub-Investigator: Konasale Prasad, M.D.
      • Sub-Investigator: Maribeth A Wesesky, BPS
      • Sub-Investigator: Ian Conner, M.D.
      • Sub-Investigator: Madhavi K Ganapathiraju, Ph.D.
      • Sub-Investigator: Roy KN Chengappa, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Written informed consent.
• Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
• PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
• Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.
• Not participating in another randomized controlled clinical trial (RCT).

Exclusion Criteria:

• Substance abuse in the past month/dependence past 6 months, (except nicotine).
• History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
• Pregnancy.
• Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
• Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
• Intellectual disability as defined in DSM 5.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Acetazolamide; acetazolamide capsules	Drug: Acetazolamide; ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.; Other Names: Diamox
Active Comparator: Placebo; Identical gelatin capsules	Drug: Placebo; Identical gelatin capsules will be prepared by filling with inert excipients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in positive symptoms	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Severity	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 30 Items, (minimum score = 7, maximum score = 210)	24 weeks
Clinical Severity	Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)	24 weeks
Cognition	Trail Making Test (TMT) 86: This test estimates attention, working memory and executive function.	24 weeks
Clinical Severity	"Clinical Global Impression - Severity" (CGI-S). The CGI-S is a 7-point scale that rates the severity of the patient's illness at the time of assessment. The minimum score is 1 and the maximum score is 100. Scores which are lower in value indicate greater severity of illness. Higher scores indicate less severe illness.	24 weeks
Social Function	"Sheehan's Disability Scale" (SDS). The SDS is a self-report is a self-report tool that assesses functional impairment in work/school, social and family life with a 10-point visual analogue scale. The minimum score is 0 and the maximum score is 10. Scores which are lower in value indicate better outcomes with less disability. Higher scores indicate more severe illness with greater disability.	24 weeks
Global Assessment of Function	"Global Assessment of Function" (GAF). The GAF is an assessor reporting tool that assesses level of functioning on a 1 to 100 point scale. The minimum score is 1 and the maximum score is 100. Scores which are higher in value indicate better outcomes with less disability. Lower scores indicate more severe illness with greater disability.	24 weeks
Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)	The QOLS was originally a 15-item instrument that measured five conceptual domains of quality of life: material and physical well-being, relationships with other people, social, community and civic activities, personal development and fulfillment, and recreation. After descriptive research that queried persons with chronic illness on their perceptions of quality of life, the instrument was expanded to include one more item: Independence, the ability to do for yourself. Thus, the QOLS in its present format contains 16 items. The QOLS is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112. The QOLS scores are summed so that a higher score indicates higher quality of life. Average total score for healthy populations is about 90.	24 weeks
Socio-Economic Status	We will use a composite measure of educational attainment and pretax family (household) income based on the Hollingshead Redlich 4-factor index. The Hollingshead Four Factor Index of Socioeconomic Status is a survey designed to measure social status of an individual based on four domains: marital status, retired/employed status, educational attainment, and occupational prestige. The participant's education code is obtained education code is rated on a 7-point scale that lists highest grade completed. The participant's occupational code is rated on a 9-point scale. SES=0.5X education score+0.3Xincome score+ 0.3X occupation score.	24 weeks
Side Effects	We will make a list of side effects for CGY noted in the Drug Formulary. This list will be a comprehensive listing of possible side effects by body system, grading both the frequency and severity of the symptoms. Frequency (days per week): Severity: 0 = Absent; = 1-2 days 1 = mild, does not interfere with functioning; = 3-4 days 2 = moderate, some interference with functioning; = 5-7 days 3 = severe, functioning is significantly impaired Frequency scores can range from 0 to 3, with higher scores equaling higher frequency. Severity scores can range from 1 to 3, with higher scores equaling greater severity.	24 weeks

Collaborators and Investigators

• Sponsor: Vishwajit Nimgaonkar, MD PhD
• Collaborators: Stanley Medical Research Institute
• Investigators: Principal Investigator: Vishwajit L Nimgaonkar, M.D., Ph.D., University of Pittsburgh

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2022
• Primary Completion (Estimated): January 31, 2025
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: December 15, 2020
• First Submitted That Met QC Criteria: May 13, 2021
• First Posted (Actual): May 14, 2021

Study Record Updates

• Last Update Posted (Actual): January 5, 2024
• Last Update Submitted That Met QC Criteria: January 4, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Schizophrenia; acetazolamide; Schizo Affective Disorder
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Psychotic Disorders; Mood Disorders; Schizophrenia, Treatment-Resistant; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Carbonic Anhydrase Inhibitors; Natriuretic Agents; Diuretics; Anticonvulsants; Acetazolamide
• Other Study ID Numbers: STUDY20010237

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No individual data will be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No